Detailed Narrative
Q3 FY25 Financial Performance Highlights
Innova Captab reported a consolidated revenue of ₹316.5 crores for Q3 FY25, marking a year-on-year growth of nearly 5%. The company demonstrated strong profitability, with its EBITDA margin expanding by 60 basis points to 16.1%. Profit After Tax (PAT) saw a significant 36.3% year-on-year increase, reaching ₹34.2 crores, and PAT margins improved to 10.8% from 8.3% in the prior year's quarter, primarily driven by enhanced EBITDA margins and reduced interest costs.
Nine Months FY25 Consolidated Performance and Segmental Mix
For the nine months ended December 31, 2024, Innova Captab achieved an overall revenue of ₹928.9 crores, reflecting a robust 13.5% year-on-year growth. The business mix for this period was dominated by CDMO, contributing 55% (₹505.1 crores), followed by domestic generics at 18% (₹169 crores), international branded generics at 12% (₹113 crores), and Sharon Bio-Medicines at 15% (₹141.9 crores).
Segmental Business Growth and Sharon's Deferred Orders
The CDMO business maintained its growth trajectory, contributing ₹172.2 crores (54% of topline) in Q3 FY25. The international business segment showed strong momentum, growing by an impressive 17% year-on-year to ₹41.2 crores in Q3. Sharon Bio-Medicines, however, experienced a 6.5% year-on-year decline in Q3 revenue to ₹44.5 crores, attributed to certain international orders worth approximately ₹4-5 crores being deferred to Q4 FY25.
Jammu Facility Commencement and Future Revenue Potential
A significant milestone was achieved with the commercial production commencement at the Kathua, Jammu facility on January 14, 2025. This new facility is projected to generate substantial incremental revenue of ₹400-500 crores in FY26, with an estimated ₹20-40 crores expected in Q4 FY25. Management anticipates peak utilization at 70-75%, which could translate to ₹1,500-1,600 crores in revenue within two to three years, with the absolute peak capacity estimated at ₹2,000 crores.
Margin Expansion and Cost Management Strategies
The company expects overall EBITDA margins to improve by 100-200 basis points in the coming years, driven by the benefits accrued from the new Jammu facility, including GST incentives and capital interest subvention. While initial operating costs for the Jammu plant are expected in Q4 FY25, management is focused on mitigating any margin headwinds by maximizing sales. The annual depreciation from the Jammu plant is estimated to be in the range of ₹20-25 crores.
API Pricing Trends and CDMO Growth Outlook
API pricing remained stable quarter-on-quarter but was slightly lower on a year-on-year basis, impacting the CDMO business. Despite this, the company reported better volumes, leading to an underlying year-on-year increase of around 7-8% at a standalone revenue level for CDMO. Management expects overall CDMO growth to be in the early teens in the coming period, driven by its robust manufacturing capabilities and product portfolio expansion.